Dr Reddy's Shares Slide 7% After Delay in Semaglutide Supplies over Quality Concerns
Dr Reddy’s said certain semaglutide batches were out of specification and it is investigating the active pharmaceutical ingredient issue while supplies are delayed.
- On Thursday, Mumbai-based Dr. Reddy's Laboratories announced it is delaying commercial supplies of semaglutide due to an issue with the active pharmaceutical ingredient, sending its stock down 5.9% in its biggest fall in more than four months.
- Dr. Reddy's rolled out generic versions including Obeda, Mashlo, and Olymviq after the patent on semaglutide expired in March 2026, competing with Danish firm Novo Nordisk's blockbuster diabetes and obesity treatments, Ozempic and Wegovy.
- The company stated, "Certain batches of semaglutide were found to be out of specification due to an issue associated with the active pharmaceutical ingredient used in the product," and is investigating the root cause to ensure quality.
- Despite the delay, Dr. Reddy's confirmed there was no impact on patient safety or existing global regulatory filings, while market research firm Pharmarack noted the company sold about 31,000 units of its GLP-1 treatments in India since March.
- Systematix Group analyst Vishal Manchanda indicated the September quarter might be weaker due to the delay, though the pharma index rose 1.8% and Nifty 50 climbed 0.6% on the day.
12 Articles
12 Articles
The batch made of Ozempic in which the 'impurity' was detected was not yet put up for sale.
Dr. Reddy's Generic Ozempic Supplies Delayed on API Issue
Dr. Reddy’s Laboratories Ltd. will delay the commercial production of its generic Ozempic drug after it found an unspecified issue with the active pharmaceutical ingredient in some batches of the anti-obesity and diabetes therapy.
India's Dr Reddy's on track for worst day in 3 years as semaglutide supplies hit
Shares of Dr Reddy's Laboratories fell as much as 6.5% on Thursday, after the Indian drugmaker said it is delaying commercial supplies of semaglutide due to an issue related to the active pharmaceutical ingredient used in the drug.
The Economic Times
Times of IndiaDr Reddy's shares slide 7% after delay in semaglutide supplies over quality concerns
Dr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue involving the active pharmaceutical ingredient (API). The company said patient safety and regulatory filings remain unaffected, while an investigation is underway to identify the root cause and restore supplies.
Coverage Details
Bias Distribution
- 60% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
